Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients

Similar Items

• Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
  by: Martini A, et al.
  Published: (2011-09-01)
• A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to <it>V198M</it> mutation responds to canakinumab - a case report
  by: Kuemmerle-Deschner Jasmin B, et al.
  Published: (2011-09-01)
• Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
  by: Ori Toker, et al.
  Published: (2010-05-01)
• Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry
  by: Ulrich A Walker, et al.
  Published: (2021-08-01)
• The interleukin 1 inhibitor canakinumab in the treatment of cryopyrin-associated periodic syndromes (CAPS): clinical experience
  by: Svetlana Olegovna Salugina, et al.
  Published: (2014-12-01)